The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
30
Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
Vanderbilt University Medical Center
Nashville, Tennessee, United States
RECRUITINGOral anticancer agent adherence by proportion of days covered (PDC)
PDC is a common medication adherence metric, and assesses the ratio of number of days the patient is supplied with oral anticancer agent, from the time of initiation until 6 months later, to the total number of days during that period. Data from the electronic medical record for dose changes will be aligned with the refill data to calculate a dose-adjusted PDC.
Time frame: Up to 6 months post-initiation
Chronic disease medication adherence
PDCs for medications for select chronic diseases will be calculated for the 6 months before and after oral anticancer agent initiation
Time frame: 6 months pre- and post-initiation of the oral anticancer agent
Patient-reported outcome measure completion
The oncology-specific patient-reported outcome measure is to be completed at 2 and 6 weeks after oral anticancer agent initiation. This measure assesses the percent of patients who complete this tool at both time points.
Time frame: Approximately 42 days after oral anticancer agent initiation
Comprehensive Medication Review (CMR) completion
Proportion of enrolled subjects completing the initial and follow-up CMRs with the community pharmacist
Time frame: Approximately 50 days after oral anticancer agent initiation
Oncology pharmacist review of patient-reported outcome measure
The patient-reported outcome measure is scored within one day after it is completed by the subject and is routed to the oncology pharmacist to review the results. The number of measures that are reviewed within 1 day of receipt will be assessed at 2 weeks and at 6 weeks.
Time frame: Approximately 44 days after oral anticancer agent initiation
Percent of Comprehensive Medication Reviews (CMRs) where note was routed to oncology pharmacist
The number of CMRs where note was routed to oncology pharmacist out of total number of completed CMRs, assessed at 2 weeks and at 6 weeks.
Time frame: Approximately 43 days after oral anticancer agent initiation
Proportion of Comprehensive Medication Reviews (CMRs) reviewed by the oncology pharmacist
The number of CMR notes reviewed by the oncology pharmacist out of the total number of completed CMRs, assessed at 2 weeks and at 6 weeks.
Time frame: Approximately 44 days after oral anticancer agent initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.